GlassScriptPhysician profile
Blessy M Jacob
NPI 1851525406
$14,697.04
in general payments reported to CMS, 2019-2025
70 companies · $3,357 in 2025
The $3,357 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,885 · 2020: $557 · 2021: $2,030 · 2022: $1,938 · 2023: $2,366 · 2024: $2,564 · 2025: $3,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,083 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125 · Education: $79.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,083.36 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125.00 |
| Education | $79.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epizyme, INC. | $1,343.07 | 2021-2024 | Onivyde, Tazverik |
| E.R. Squibb & Sons, L.L.C. | $1,230.25 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $1,022.89 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Novartis Pharmaceuticals Corporation | $846.35 | 2019-2025 | |
| Celgene Corporation | $728.54 | 2019-2025 | Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals LP | $679.61 | 2019-2025 | Calquence, Enhertu, Lynparza |
| Lilly USA, LLC | $623.94 | 2019-2025 | Jaypirca, Verzenio |
| Pfizer INC. | $593.21 | 2019-2025 | |
| Daiichi Sankyo INC. | $577.55 | 2019-2025 | Enhertu |
| Gilead Sciences, INC. | $444.20 | 2021-2025 | Trodelvy |
| Janssen Biotech, INC. | $441.57 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Incyte Corporation | $434.96 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Genentech USA, INC. | $360.44 | 2019-2024 | Polivy, Rozlytrek, Alecensa |
| Exelixis INC. | $347.85 | 2021-2025 | Cabometyx |
| Astellas Pharma US INC | $289.58 | 2019-2025 | Padcev, Vyloy, Xospata |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $268.69 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $267.04 | 2019-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Array Biopharma INC | $260.46 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Genmab U.S., INC. | $229.18 | 2023-2025 | Epkinly |
| Abbvie INC. | $223.10 | 2019-2025 | |
| Genzyme Corporation | $222.18 | 2019-2025 | |
| Kite Pharma, INC. | $209.37 | 2022-2025 | Yescarta |
| Bayer Healthcare Pharmaceuticals INC. | $194.59 | 2022-2025 | |
| Acrotech Biopharma INC. | $178.65 | 2023-2024 | Beleodaq |
| Jazz Pharmaceuticals INC. | $172.61 | 2019-2025 | |
| Puma Biotechnology, INC. | $163.67 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $135.86 | 2022-2025 | Ultomiris |
| Emd Serono, INC. | $132.51 | 2020-2025 | Bavencio |
| Seagen INC. | $128.23 | 2021-2023 | Tukysa, Padcev |
| Dova Pharmaceuticals | $118.93 | 2019-2021 | |
| Eisai INC. | $104.37 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $102.37 | 2023 | Tazverik |
| Beigene USA, INC. | $100.95 | 2023-2025 | Brukinsa |
| Sobi, INC | $95.75 | 2022-2025 | |
| Pharmaessentia USA Corporation | $93.49 | 2023-2025 | Besremi |
| Sumitomo Pharma America, INC. | $91.83 | 2023-2025 | Orgovyx |
| Dendreon Pharmaceuticals LLC | $84.34 | 2023-2025 | Provenge |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.85 | 2025 | |
| Amgen INC. | $64.36 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $61.10 | 2019-2023 | Imbruvica |
| Myriad Genetic Laboratories, INC. | $60.30 | 2025 | Myrisk |
| Rigel Pharmaceuticals, INC. | $55.55 | 2024 | Rezlidhia, Tavalisse |
| Stemline Therapeutics INC. | $51.44 | 2024-2025 | Orserdu |
| Myovant Sciences INC. | $50.03 | 2022 | |
| Mirati Therapeutics, INC. | $42.00 | 2023-2024 | Krazati |
| Beone Medicines USA, INC. | $41.91 | 2025 | Tevimbra, Brukinsa |
| Janssen Scientific Affairs, LLC | $41.18 | 2025 | Carvykti, Talvey, Tecvayli |
| Tersera Therapeutics LLC | $40.21 | 2019-2020 | |
| Immunogen, INC. | $39.58 | 2023-2024 | Elahere, Elahere |
| Regeneron Healthcare Solutions, INC. | $37.30 | 2019-2024 | Libtayo |
| Siemens Medical Solutions USA, INC. | $35.85 | 2025 | Naeotom Alpha, Microthermx Microwave Ablation System |
| Agios Pharmaceuticals, INC. | $35.72 | 2023-2025 | Pyrukynd |
| Pharmacosmos Therapeutics INC. | $34.76 | 2024-2025 | Monoferric |
| Adc Therapeutics America, INC. | $33.97 | 2021-2023 | |
| Partner Therapeutics, INC. | $33.56 | 2019 | |
| Karyopharm Therapeutics INC. | $31.30 | 2020-2025 | Xpovio |
| Recordati_rare_diseases_inc. | $24.28 | 2025 | Enjaymo |
| Coherus Oncology, INC. | $24.03 | 2022 | |
| Fennec Pharmaceuticals, INC. | $23.44 | 2024 | Pedmark |
| Geron Corporation | $22.66 | 2025 | Rytelo |
| Aveo Pharmaceuticals, INC. | $22.37 | 2025 | |
| Syndax Pharmaceuticals, INC. | $22.04 | 2025 | |
| Springworks Therapeutics, INC. | $21.89 | 2025 | Ogsiveo |
| Amag Pharmaceuticals, INC. | $21.54 | 2022 | |
| Servier Pharmaceuticals LLC | $21.45 | 2023 | |
| Cti Biopharma Corp. | $20.75 | 2023 | Vonjo |
| Ge Healthcare | $18.51 | 2022 | |
| Deciphera Pharmaceuticals INC. | $17.32 | 2022 | |
| Taiho Oncology, INC. | $16.57 | 2024 | |
| Verastem, INC. | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blessy Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.